We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. The company has additional operations facilities in Huntsville, Alabama... Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. The company has additional operations facilities in Huntsville, Alabama, and Hyderabad, India. Show more
Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence PR Newswire SAN FRANCISCO, Nov. 18, 2024...
Nektar Therapeutics Reports Third Quarter 2024 Financial Results PR Newswire SAN FRANCISCO, Nov. 7, 2024 SAN FRANCISCO, Nov. 7, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today...
Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.34 | -24.8175182482 | 1.37 | 1.375 | 1.02 | 1845938 | 1.13355153 | CS |
4 | -0.37 | -26.4285714286 | 1.4 | 1.47 | 1.02 | 1725974 | 1.2850927 | CS |
12 | -0.33 | -24.2647058824 | 1.36 | 1.49 | 1.02 | 1280379 | 1.2903383 | CS |
26 | -0.73 | -41.4772727273 | 1.76 | 1.77 | 1.01 | 1514274 | 1.2929717 | CS |
52 | 0.55 | 114.583333333 | 0.48 | 1.928 | 0.4227 | 1691435 | 1.13775955 | CS |
156 | -10.7882 | -91.2846287929 | 11.8182 | 15.945 | 0.4126 | 2850129 | 2.81565347 | CS |
260 | -17.11 | -94.3219404631 | 18.14 | 29 | 0.4126 | 2199652 | 6.68862132 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions